These results indicated specific peptide targeting SLC39A1 by interfering combination of full‐length SLC39A1 and DRP1 inhibits cell proliferation and tumour growth, which offers a promising novel strategy for HCC treatment. Here, DNM1L is linked to hepatocellular carcinoma.